VERA
Vera Therapeutics, Inc.Healthcare · $2.3B market cap
Verdict
We can't put a fair value on VERA right now. It has lost money in each of its last 3 years, and our valuation needs recent profits to project from.
Business quality
1 of 5 clear the 10% bar. What are the Big Five?
Follow VERA
Track it on your watchlist and see the full analysis. Free.
Create a free accountInsider activity
Since Sep 2, 2026: no open-market purchases, 1 sale worth $650K and 1 other filing (stock awards, tax withholding and similar). Why purchases matter
Sales
Other filings
About Vera Therapeutics, Inc.
Vera Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development and commercialization of treatments for significant immunological disorders, primarily within the United States. Their leading therapeutic candidate is atacicept, a fusion protein that patients self-administer as a subcutaneous injection. This drug is currently undergoing Phase IIb clinical trials to treat immunoglobulin A…
Biotechnology
Fair value and Payback Price are estimates from the company's reported financials, not investment advice. Prices as of the close of Oct 3, 2026. How the Payback Price works